Meros Investment Management LP Has $4.12 Million Position in InfuSystem Holdings, Inc. (NYSE:INFU)

Meros Investment Management LP reduced its holdings in shares of InfuSystem Holdings, Inc. (NYSE:INFU) by 0.2% during the 3rd quarter, Holdings Channel.com reports. The fund owned 614,927 shares of the company’s stock after selling 1,211 shares during the period. InfuSystem accounts for about 1.9% of Meros Investment Management LP’s portfolio, making the stock its 26th largest position. Meros Investment Management LP’s holdings in InfuSystem were worth $4,120,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in INFU. BNP Paribas Financial Markets lifted its holdings in InfuSystem by 66.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after purchasing an additional 1,626 shares during the last quarter. Rhumbline Advisers lifted its holdings in InfuSystem by 13.8% during the 2nd quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock valued at $121,000 after purchasing an additional 2,145 shares during the last quarter. State Street Corp raised its stake in shares of InfuSystem by 1.1% in the third quarter. State Street Corp now owns 267,012 shares of the company’s stock worth $1,789,000 after acquiring an additional 3,019 shares during the last quarter. ARS Investment Partners LLC raised its stake in shares of InfuSystem by 11.4% in the second quarter. ARS Investment Partners LLC now owns 33,510 shares of the company’s stock worth $229,000 after acquiring an additional 3,422 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of InfuSystem by 6.1% in the second quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock worth $641,000 after acquiring an additional 5,391 shares during the last quarter. 71.13% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

INFU has been the subject of a number of research analyst reports. B. Riley initiated coverage on shares of InfuSystem in a research note on Thursday, September 26th. They issued a “buy” rating and a $13.00 target price for the company. StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th.

InfuSystem Price Performance

Shares of NYSE:INFU opened at $8.99 on Wednesday. InfuSystem Holdings, Inc. has a one year low of $5.74 and a one year high of $10.99. The business’s 50 day simple moving average is $7.76. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The firm has a market cap of $191.16 million, a PE ratio of 149.83 and a beta of 1.53.

Insider Transactions at InfuSystem

In related news, CEO Richard Dilorio sold 5,398 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $8.87, for a total transaction of $47,880.26. Following the completion of the transaction, the chief executive officer now owns 416,659 shares in the company, valued at approximately $3,695,765.33. The trade was a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.20% of the stock is owned by corporate insiders.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.